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INTRODUCTION
Atopic dermatitis (AD) is a chronic, relapsing, inflammatory 
skin disease characterized by severe pruritus and eczematous 
skin lesions.1 Lichenified plaques and itching all day long and 
even worse at night, causing loss of sleep (LOS), are debilitat-
ing. Various treatment methods have been introduced, in-
cluding emollients, topical steroids, topical calcineurin inhibi-
tors, systemic immunosuppressants and/or phototherapy,2 
but none of these are curative. In some AD patients, there is 
convincing evidence that allergens, especially the house dust 
mite (HDM), play a relevant role in eliciting or aggravating the 
eczematous skin lesions and may contribute to eczema flare-
ups.3,4 The nature of the skin inflammation in AD has raised a 
growing interest in treatment with allergen-specific immuno-
therapy (SIT).3 Besides, SIT has been used as the only specific 
therapy in allergic disease, such as allergic rhinitis, mild aller-
gic asthma and bee venom anaphylaxis.4-6 Several studies with 
AD patients have been reported, but most include small sam-
ple sizes and usually a maximum of one year of follow-up.7-10 
Our clinic has designed a protocol to maintain SIT for at least 
3 years or more, as patients tend to keep improving even after 
one year of treatment. To evaluate the efficacy of long-term 
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treatment with HDM-SIT, we performed a retrospective analy-
sis of over 200 AD patients. 
MATERIALS AND METHODS
Subjects and treatment
Study subjects were selected by retrospective review of medi-
cal records at the Yonsei University Severance Hospital outpa-
tient clinic in the Department of Dermatology. Medical records 
between 1995 and 2012 were reviewed as approved by the In-
stitutional Review Board. A total of 217 extrinsic AD patients 
treated with SIT for at least 3 years were selected. Among them, 
70 (32.3%) patients were characterized as having severe AD 
with an investigator global assessment (IGA) above 4 at base-
line evaluation, 106 (48.8%) as moderate AD with an IGA of 3, 
and 41 (18.9%) as mild AD with an IGA of 2. There were no pa-
tients with an IGA of 1. The male to female ratio was 49.6:50.4. 
The mean patient age was 21.16±8.46 (mean±standard devia-
tion) years (Table 1). Subjective symptoms of pruritus and LOS 
were scored using the visual analogue scale (VAS). Skin prick 
test (SPT) was performed with 55 allergens (30 inhalants and 
25 food allergens) and ImmunoCAP-test was done with 6 
commonly offending allergens including egg white, milk, soy-
bean, wheat, Dermatophagoides pteronyssinus (D. pteronyssi-
nus) and Dermatophagoides farinae (D. farinae). Wheal diam-
eters ≥3 mm in about 15 minutes after the test a were considered 
positive in SPT and ≥3.5 kU/L in CAP-test were regarded as posi-
tive. Initially, candidates for SIT were selected through total 
IgE and CAP-test or SPT results showing hypersensitivity to 
HDM. A HDM allergen extract containing a mixture of D. ptero-
nyssinus and D. farinae extracts (50:50%) adsorbed to tyrosine 
(Tyrosine-s®; Allergy Therapeutics Inc., West Sussex, United 
Kingdom) was used according to the manufacturer’s instruc-
tions. Treatment schedules included two stages: an induction 
phase and a maintenance phase. During the induction phase, 
both vial #1 (5 mL, green, 1/8 dilution of vial #2) and vial #2 (5 
mL, red, with maximum allergen extract) were used. We slowly 
escalated the HDM extract dosage to safely induce desensiti-
zation every week for 16 to 18 weeks following the manufac-
turer’s instructions. When the maintenance dosage was reached 
(1 mL of red vial), the patient visited the clinic a total of four 
times bi-weekly with following visits occurring monthly, and the 
treatment continued for 3 to 6 years depending on the patients’ 
response. Post-treatment clinical outcome was measured at the 
end of treatment session. 
Data analysis
Patient IGA, pruritus scores, LOS using VAS, total serum IgE, 
and eosinophil counts were collected. We established our own 
scoring system reflecting IGA and subjective symptoms in-
cluding pruritus and LOS to combine both physician and pa-
tient evaluations. We scored from 0 to 5 to estimate the overall 
clinical response: 0, aggravation of clinical symptom; 1, no im-
provement; 2, mild improvement with no change in IGA but 
reduction of pruritus; 3, good response with less than 2 points 
of improvement of IGA and subjective symptom improvement; 
4, excellent response with more than 2 points of improvement 
of IGA to near-complete remission with symptom improve-
ment; and 5, complete remission with an IGA of 0 with very 
mild or no symptoms. Patients were additionally classified into 
four groups according to age, initial disease severity, duration 
of treatment, and the number of allergen sensitizations. We 
used IBM SPSS statistics software, version 19.0 (SPSS Inc., Chi-
cago, IL, USA) to analyze data with significance thresholds of 
p<0.05 and p<0.01. As a further evaluation, we compared base-
line laboratory factors including total IgE and eosinophil counts 
from two groups: good SIT responders and poor SIT respond-
ers. We defined those with clinical response scores between 3 
and 5 as good responders and those with clinical response 
scores between 0 and 2 as poor responders. 
RESULTS
Clinical improvement of 217 patients was judged by using the 
IGA together with patients’ subjective assessment of symptoms 
using VAS score. The mean IGA was significantly reduced from 
3.12±0.71 to 1.08±1.24 (p=0.001) after SIT. Also, according to 
the eczema area and severity index (EASI) score data of 124 pa-Table 1. Baseline Demographics of AD Patients Who Were Treated 
with SIT for at Least Three Years (n=217)
Age (yr) 21.16±8.46 
Male:female ratio 49.6:50.4
IGA, n (%) 
Severe 70 (32.3)
Moderate 106 (48.8)
Mild 41 (18.9)
Pruritus (VAS) 5.75±2.29
LOS (VAS) 4.24±2.42
yr, years; IGA, investigator global assessment; VAS, visual analogue scale; 
LOS, loss of sleep; AD, atopic dermatitis; SIT, specific immunotherapy.
Data were expressed as mean±SD. 
Table 2. Post-Treatment Outcome in Extrinsic AD Patients with Three 
Years of SIT (n=217)
Pre-treatment Post-treatment p value
IGA 3.12±0.71 1.08±1.24 <0.01
Pruritus (VAS) 5.75±2.29 1.38±2.12 <0.01
LOS (VAS) 4.24±2.43 0.88±1.65 <0.01
Total lgE (kU/L) 2071.88±1757.3 1319.23±1384.68 <0.01
Eosinophil (count/μL) 604.71±303.40 432.22±222.58 0.103
IGA, investigator global assessment; VAS, visual analogue scale; LOS, loss 
of sleep; AD, atopic dermatitis; SIT, specific immunotherapy.
Data were expressed as mean±SD.
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ment response (p=0.147). Nevertheless, patients with moderate 
to severe AD presenting an initial IGA over 3 responded better 
to SIT treatment than patients with mild AD (p=0.036). When 
patients were grouped by the number of allergens to which 
they were sensitized, patients who were sensitized only to HDM 
had a tendency to respond better than those who also showed 
positive SPT results to other food or inhalant allergens and/or 
who are sensitized to other allergens mainly including egg 
white, milk, soybean, wheat according to CAP-test results, but 
results between two groups were not significant (p=1.051) (Fig. 3). 
tients, significant improvement was still observed after SIT 
(from 17.47±13.19 to 2.86±4.74, p<0.001). Pruritus and LOS were 
also significantly reduced (Table 2). We defined VAS 1–3 as 
mild symptom, 4–6 as moderate symptom, and 7–10 as severe 
symptom. Before the treatment, 175 (80.6%) patients had suf-
fered from moderate to severe pruritus and 120 (55.3%) pa-
tients suffered severe to moderate LOS. In a post-treatment eval-
uation, only seven (3.2%) patients exhibited severe pruritus 
and 23 (10.6%) exhibited moderate pruritus. Other patients 
had mild to no itching sensation. Additionally, only 14 (6.5%) 
patients suffered from severe to moderate sleep disturbance 
while 203 (93.5%) patients experienced mild to no LOS (p< 
0.001). Clinically, 192 patients (88.4%) improved, with 138 pa-
tients (63.6%) achieving complete or near-complete remission 
with mild itch only and no significant skin lesions (Fig. 1). The 
mean value of total serum IgE significantly decreased from 
2071.88±1757.3 kU/L to 1319.23±1384.68 kU/L (p=0.012); how-
ever, eosinophil counts insignificantly decreased (p=0.103). 
Side effects were reported in 2 patients (less than 1%) includ-
ing urticaria, localized eruption, pruritus, transient exacerba-
tion of previous atopic lesions, and relapse of previously diag-
nosed asthma. All side effects were very mild and controlled 
well with antihistamines or resolved spontaneously. 
We additionally performed three different subgroup analy-
ses according to patient’s age, AD severity and the number of 
allergens that patients were sensitized. When patients were 
grouped according to age, better SIT outcomes were observed 
in those patients under 12 years of age (p=0.024), while patients 
over 18 years of age experienced the least improvement (Fig. 
2). When patients were grouped by AD severity, the mild (IGA 
0–2), moderate (IGA 3), and severe (IGA 4–5) groups all showed 
significant clinical improvement (Table 3); however, AD se-
verity was not significantly correlated with the degree of treat-
Table 3. Baseline Severity of AD Patients and Treatment Effect of SIT 
(n=217)
IGA pre-tx IGA post-tx p value
Mild 2 0.55±0.67 <0.01
Moderate 3 1.07±1.04 <0.01
Severe 4 1.41±1.62 <0.01
IGA, investigator global assessment; AD, atopic dermatitis; SIT, specific im-
munotherapy.
Data were expressed as mean±SD.
Fig. 1. Overall treatment response of allergen-specific immunotherapy. 
Among 217 patients, 98 patients (45.2%) showed clinical remission, 40 pa-
tients (18.3%) exhibited excellent response. Parenthesized numbers refer 
to estimated overall clinical response scores.
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Fig. 2. Subgroup analysis according to patients’ age. Patients with age 
under 12 showed better treatment response when compared with ado-
lescents and adults. *p<0.05. ns, not significant.
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Fig. 3. Subgroup analysis according to the number of allergen sensitiza-
tion. Patients who were only sensitized to HDM were defined as mono-
sensitized patients, and multi-sensitized patients showed positive results 
not only with HDM but also with other food and inhalant allergens. Mono-
sensitized patients presented a tendency to respond better than the multi-
sensitized group but did not show statistical significance (p>0.05). HDM, 
house dust mite. 
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To evaluate parameters for predicting treatment outcome, 
we compared the initial total serum IgE levels and eosinophil 
counts of good responders to those of poor responders. The 
mean total IgE level and eosinophil counts were 2098.03± 
1756.72 kU/L and 618.35±324.58 count/μL, respectively, in 
good responders and 1944.06±1805.40 kU/L and 544.29±178.57 
count/μL, respectively, in poor responders. No significant dif-
ferences were observed between two groups at baseline (p= 
0.248 and 0.736). However, both were significantly reduced 
only in good responders (Table 4). We additionally analyzed 
the duration of treatment in both groups, since the duration of 
treatment might have affected the treatment outcome. How-
ever, both good and poor responders groups showed same 
mean treatment duration (3.3 years). 
Upon additional review of medical records, we identified 15 
patients who reached complete remission within three years. 
The mean age of these 15 patients was 13.33±6.58 years, and 
male to female ratio was 46.7:53.3. Mean treatment duration 
was 2.13±0.61 (Table 5). Total serum IgE was significantly re-
duced (p<0.027) in these patients; however, we could not assess 
eosinophil counts due to inadequate information (Table 6). 
DISCUSSION
The goal of SIT is to induce allergen-specific tolerance there-
fore, it is also known as allergen vaccination.11 By inducing al-
lergen-specific regulatory T cells (Tregs), the patient can ac-
quire immune tolerance against the antigen of interest.12,13 SIT-
mediated induction of Tregs expressing interleukin (IL)-10 and 
transforming growth factor β elicits the early desensitization 
phase of mast cells, basophils, and eosinophils. These Tregs 
also inhibit IgE production by suppressing Th2 cells.14 In addi-
tion, they also stimulate the expression of IgG4, a non-inflam-
matory immunoglobulin isotype.1,15,16 SIT treatment also sup-
presses IL-3, IL-4, IL-5, IL-9, and IL-13, cytokines which are 
expressed by Th2 cells and play an important role in the activa-
tion, differentiation, and survival of mast cells, eosinophils, and 
basophils.1
Despite the reported controversial effects associated with 
SIT, several randomized controlled trials revealed significant 
improvement of clinical symptoms after SIT, and, follow-up 
meta-analyses have confirmed SIT-associated improvements.17 
We recently analyzed 8 RCTs, which comprised 385 patients, 
and observed that SIT significantly improved AD symptoms 
[odds ratio (OR), 5.35; 95% confidence interval (CI), 1.61–
17.77; number needed to treat, 3; 95% CI, 2–9]. SIT also exhib-
ited significant efficacy in long-term treatment (OR, 6.42; 95% 
CI, 1.50–27.52), for patients with severe AD (OR, 3.13; 95% CI, 
1.31–7.48), and also when administered subcutaneously (OR, 
4.27; 95% CI, 1.36–13.39).
In the present study, we performed additional four different 
subgroup analyses according to patients’ age, initial AD sever-
ity, duration of treatment, and the number of sensitized aller-
gens. First, the subgroup with patients under 12 years of age 
exhibited better treatment outcome when compared with old-
er patient groups. In our meta-analysis, a subgroup analysis of 
children who underwent SIT did not reveal significant associ-
Table 4. Treatment Effect in Good Responders and Poor Responders (n=217)
Good responders (n=183) Poor responders (n=34)
Pre-treatment Post-treatment p value Pre-treatment Post-treatment p value
IGA 3.09±0.73 0.70±0.86 <0.01 3.33±0.69 3.17±0.79 0.068
Pruritus (VAS) 5.74±2.21 0.71±1.15 <0.01 5.78±2.71 5±2.52 0.025
LOS (VAS) 4.19±2.46 0.38±0.80 <0.01 4.56±2.31 3.56±2.38 0.024
Total lgE (kU/L) 2098.03±1756.72 1303.86±1511.37 <0.01 1944.05±1805.4 1393.5±488.03 0.439
Eosinophil (count/μL) 618.35±324.58 388.33±236.41 <0.05 544.29±178.57 378.67±156.31 0.818
IGA, investigator global assessment; VAS, visual analogue scale; LOS, loss of sleep.
Data were expressed as mean±SD.
Table 5. Baseline Demographics of AD Patients Who Reached Remis-
sion within Three Years of SIT (n=15)
Age (yr) 13.33±6.58
Male:female ratio 44.4:55.6
Duration of SIT (yr), n (%)
1< and <2 3 (20)
2 2 (13)
2< and <3 10 (67)
IGA, n (%)
Severe 3 (20)
Moderate 12 (80)
Mild 0 (0)
Pruritus (VAS) 6.0±2.64
LOS (VAS) 4.0±1.93
yr, years; IGA, investigator global assessment; VAS, visual analogue scale; 
LOS, loss of sleep; AD, atopic dermatitis; SIT, specific immunotherapy.
Data were expressed as mean±SD. 
Table 6. Effects of SIT in Patients Who Reached Complete Remission 
within Three Years (n=15)
Pre-treatment Post-treatment p value
IGA 3.22±0.44 0.89±1.45 <0.01
Pruritus (VAS) 6.0±2.64 0.14±0.33 <0.01
LOS (VAS) 4.0±1.94 0.12±0.71 <0.01
Total lgE (kU/L) 2339.5±259.51 1714±124.45 <0.05
IGA, investigator global assessment; VAS, visual analogue scale; LOS, loss 
of sleep; SIT, specific immunotherapy.
Data were expressed as mean±SD. 
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ations between age and treatment outcome.17 However, the 
analysis had a limitation of including a small number of stud-
ies and patients, thus being a preliminary result. AD usually 
starts during childhood, with a high proportion of patients un-
dergoing spontaneous remission. In severe cases, however, AD 
persists until adulthood or starts, relapses, or aggravates later 
in life.18,19 Severe disease course in adult AD can be one expla-
nation for relatively unsuccessful treatment response observed 
in older patients in our current study. Moreover, chronic dis-
ease associated with defined, large areas of lichenification-
thick, leathery skin due to a chronic inflammation is harder to 
treat. Additionally, genetic predisposition (for example, a mu-
tation in the filaggrin gene) resulting in an impaired skin bar-
rier, has recently been identified as an another risk factor for 
severe, persistent AD.20-24 Prolonged immune system dysregu-
lation may also affect SIT response differentially with patient 
age, but additional studies are needed to identify precise mech-
anism in this interaction.
A randomized, double-blinded, placebo controlled study done 
by Novak, et al.25 demonstrated that only patients with a total 
Severity Scoring of Atopic Dermatitis (SCORAD) >50 signifi-
cantly responded to SIT. In our current study, AD severity did 
not significantly correlate with treatment efficacy, but patients 
with moderate to severe AD IGA responded significantly bet-
ter to SIT, and they were more likely to reach near-complete to 
complete remission. Patients with mild AD also responded 
well to the therapy. In brief, all AD patients in our study bene-
fitted from SIT regardless of disease severity. Further controlled 
studies are needed to confirm the efficacy of SIT in mild AD 
patients. 
Our data did not indicate that the effect of SIT was directly as-
sociated with treatment duration when the treatment was giv-
en for more than three years. Meta-analyses revealed success 
with long-term treatment (over one year); however, most pa-
tients did not reach near complete to complete remission, and 
there are no specific established guidelines for how long treat-
ment should be maintained. When compared to the previous 
randomized double blind, placebo controlled studies done 
after one year of treatment, we found better treatment respons-
es after three years of therapy. Therefore, we propose that 
therapeutic success can be achieved not only in patients with 
severe AD but also in other AD patients with long-term SIT 
treatment (over three years). 
Patients mono-sensitized to HDM had a better outcome 
than multi-sensitized patients; however, this difference in treat-
ment outcome was not significant. Although some patients 
were multi-sensitized to other allergens, multi-sensitized pa-
tients can also benefit from the treatment since HDM is thought 
to be the most potent exacerbating factor. More effective treat-
ment approaches for multi-sensitized patients should be con-
sidered in future studies. 
We also analyzed total serum IgE levels and eosinophil counts, 
both at baseline and after treatment. Both were reduced after 
treatment, but there was no significant difference between 
good and poor responders at baseline. Furthermore, although 
both IgE and eosinophils significantly decreased in good re-
sponders, they did not correlate with clinical improvement. 
Currently, there are no biomarkers for predicting SIT outcome 
in AD patients. Many clinicians and scientists are working to 
identify such biomarkers, but this is a very challenging task 
because AD is multifactorial disease associated with a com-
plex immunologic reaction. Nevertheless, we expect a forth-
coming surge in biomarker discovery, which can predict, as-
sess, and standardize treatment responses in the near future. 
Considering that this is a retrospective study analyzing the 
data from AD patients who received SIT for more than three 
years, several limitations exist. First, since not all the patients 
had SCORAD or EASI scores, we had to use IGA which is less 
objective than other methods. However, we used our own scor-
ing system in evaluating final treatment outcome by combin-
ing the pruritus and LOS result, which is similar to SCORAD 
system. Second, there may be a selection bias that could result 
in more favorable outcome. “Three years of treatment” could 
mean that patients were tolerating the procedure because it 
had been effective, while those who did not experience symp-
tomatic improvement may have dropped out. And also, it was 
difficult to precisely evaluate patients’ compliance since it was 
a retrospective analysis which might have resulted in statisti-
cal bias. When we reviewed our records from 1995 to 2012, only 
about 11.9% of patients had decided to withdraw from the 
treatment regimen. These patients included those who were 
unable to maintain SIT or had to postpone the maintenance 
therapy due to military service, getting a new job, moving to an-
other location, or studying abroad. As we did not have a con-
trol group, there is a chance that the observed beneficial effects 
could be due to other oral or topical medications, especially 
among those patients with milder AD. However, because SIT 
is usually given considering not only disease severity but also 
the long-standing and recurrent history of disease, treatment 
responses might reflect the effect of SIT. Lastly, we were un-
able to distinguish remission after SIT from natural remission. 
Even though persistent AD is increasing and about 60% of pa-
tients have AD still in their adulthood,26 it is not possible to 
differentiate the spontaneous remission from successful treat-
ment result. Further studies with a control group are necessary 
to confirm the age-related treatment efficacy. 
As mentioned above, there have been several studies on the 
efficacy of one year SIT treatment regimens. Nonetheless, the 
merit of our current study is a long-term (more than three years) 
SIT treatment efficacy. Only 15 patients reached complete re-
mission within three years and the number is far less than that 
of patients reaching complete remission after more than three 
years of SIT (98 patients). In the future study, we will compare; 
long-term treatment efficacy more thoroughly the SIT efficacy 
at one year, two years.
In conclusion, we emphasize the usefulness of HDM SIT as 
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the only curative strategy for AD. Starting therapy at a younger 
age and maintaining long-term treatment (more than three 
years) may be necessary to achieve a good outcome. Although 
patients with more severe AD and mono-sensitized patients 
were more likely to experience better treatment outcomes, oth-
er patients also benefitted from the treatment. Optimizing 
preparation with more refined specific antigenic peptides from 
major allergens,27 and the use of potent adjuvants would im-
prove the treatment outcome. Identification of a good biomark-
er to predict, assess, and standardize treatment efficacy is ex-
pected to develop an advanced SIT application in the future. 
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